Overdiagnosis: Difference between revisions
Jump to navigation
Jump to search
imported>Bruce M. Tindall mNo edit summary |
imported>Robert Badgett No edit summary |
||
| Line 2: | Line 2: | ||
In [[epidemiology]] and [[mass screening]], '''overdiagnosis''' is the diagnosis of non-harmful disease.<ref name="pmid8464435">{{cite journal |author=Black WC, Welch HG |title=Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy |journal=N. Engl. J. Med. |volume=328 |issue=17 |pages=1237–43 |year=1993 |month=April |pmid=8464435 |doi= |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=8464435&promo=ONFLNS19 |issn=}}</ref> Overdiagnosis inflates the importance of the screening problem. | In [[epidemiology]] and [[mass screening]], '''overdiagnosis''' is the diagnosis of non-harmful disease.<ref name="pmid8464435">{{cite journal |author=Black WC, Welch HG |title=Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy |journal=N. Engl. J. Med. |volume=328 |issue=17 |pages=1237–43 |year=1993 |month=April |pmid=8464435 |doi= |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=8464435&promo=ONFLNS19 |issn=}}</ref> Overdiagnosis inflates the importance of the screening problem. | ||
Overdiagnosis has been shown to occur in the screening of breast cancer (rate may 10% | Overdiagnosis has been shown to occur in the screening of breast cancer (rate may 10%<ref name="pmid16517548">{{cite journal |author=Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP |title=Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study |journal=BMJ |volume=332 |issue=7543 |pages=689–92 |year=2006 |month=March |pmid=16517548 |pmc=1410836 |doi=10.1136/bmj.38764.572569.7C |url=http://bmj.com/cgi/pmidlookup?view=long&pmid=16517548 |issn=}}</ref> or higher<ref name="pmid19589821">{{cite journal| author=Jørgensen KJ, Gøtzsche PC| title=Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. | journal=BMJ | year= 2009 | volume= 339 | issue= | pages= b2587 | pmid=19589821 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19589821 | doi=10.1136/bmj.b2587 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>), lung cancer (rate may be 2%)<ref name="pmid16757699">{{cite journal |author=Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP, Fontana RS |title=Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis |journal=J. Natl. Cancer Inst. |volume=98 |issue=11 |pages=748–56 |year=2006 |month=June |pmid=16757699 |doi=10.1093/jnci/djj207 |url=http://jnci.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=16757699 |issn=}}</ref>, and prostate cancer (rate may be 15% in whites and 37% in blacks)<ref name="pmid12096083">{{cite journal |author=Etzioni R, Penson DF, Legler JM, ''et al'' |title=Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends |journal=J. Natl. Cancer Inst. |volume=94 |issue=13 |pages=981–90 |year=2002 |month=July |pmid=12096083 |doi= |url=http://jnci.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=12096083 |issn=}}</ref>. | |||
Overdiagnosis can be prevented by studying the screening program with a [[randomized controlled trial]] in which one arm of the trial the subjects are randomly assigned to the screening program and in the other arm of the trial, subjects are assigned to the control group. Examiniation of the rate of diagnosis over time detects overdiagnosis: <ref name="pmid16757699">{{cite journal |author=Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP, Fontana RS |title=Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis |journal=J. Natl. Cancer Inst. |volume=98 |issue=11 |pages=748–56 |year=2006 |month=June |pmid=16757699 |doi=10.1093/jnci/djj207 |url=http://jnci.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=16757699 |issn=}}</ref> | Overdiagnosis can be prevented by studying the screening program with a [[randomized controlled trial]] in which one arm of the trial the subjects are randomly assigned to the screening program and in the other arm of the trial, subjects are assigned to the control group. Examiniation of the rate of diagnosis over time detects overdiagnosis: <ref name="pmid16757699">{{cite journal |author=Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP, Fontana RS |title=Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis |journal=J. Natl. Cancer Inst. |volume=98 |issue=11 |pages=748–56 |year=2006 |month=June |pmid=16757699 |doi=10.1093/jnci/djj207 |url=http://jnci.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=16757699 |issn=}}</ref> | ||
Revision as of 06:13, 15 September 2009
In epidemiology and mass screening, overdiagnosis is the diagnosis of non-harmful disease.[1] Overdiagnosis inflates the importance of the screening problem.
Overdiagnosis has been shown to occur in the screening of breast cancer (rate may 10%[2] or higher[3]), lung cancer (rate may be 2%)[4], and prostate cancer (rate may be 15% in whites and 37% in blacks)[5].
Overdiagnosis can be prevented by studying the screening program with a randomized controlled trial in which one arm of the trial the subjects are randomly assigned to the screening program and in the other arm of the trial, subjects are assigned to the control group. Examiniation of the rate of diagnosis over time detects overdiagnosis: [4]
- "If overdiagnosis has not occurred, the cumulative number of cases in each arm will equalize with time after screening stops (i.e., catch-up) as the counterparts of the earlier screen-detected cancers are detected symptomatically in the control arm."
- "If overdiagnosis has occurred, the number of cases in both arms will never equalize because the excess cases in the intervention arm will have no counterparts in the control arm."
References
- ↑ Black WC, Welch HG (April 1993). "Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy". N. Engl. J. Med. 328 (17): 1237–43. PMID 8464435. [e]
- ↑ Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP (March 2006). "Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study". BMJ 332 (7543): 689–92. DOI:10.1136/bmj.38764.572569.7C. PMID 16517548. PMC 1410836. Research Blogging.
- ↑ Jørgensen KJ, Gøtzsche PC (2009). "Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends.". BMJ 339: b2587. DOI:10.1136/bmj.b2587. PMID 19589821. Research Blogging.
- ↑ 4.0 4.1 Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP, Fontana RS (June 2006). "Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis". J. Natl. Cancer Inst. 98 (11): 748–56. DOI:10.1093/jnci/djj207. PMID 16757699. Research Blogging.
- ↑ Etzioni R, Penson DF, Legler JM, et al (July 2002). "Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends". J. Natl. Cancer Inst. 94 (13): 981–90. PMID 12096083. [e]